Document is current
Any future updates will be listed below
-
Authors
Hosseini, Amir https://orcid.org/0000-0001-8229-832X
Dhall, Abhinav
Ikonen, Nemo https://orcid.org/0000-0003-4022-4394
Sikora, Natalia https://orcid.org/0000-0001-6457-6365
Nguyen, Sylvain https://orcid.org/0000-0002-6508-1337
Shen, Yuqi https://orcid.org/0009-0008-9114-8743
Amaral, Maria Luisa Jurgensen
Jiao, Alan
Wallner, Felice
Sergeev, Philipp https://orcid.org/0000-0002-0234-1568
Lim, Yuhua https://orcid.org/0009-0008-3084-3654
Yang, Yuanqin
Vick, Binje https://orcid.org/0000-0003-1956-2778
Kawabata, Kimihito Cojin
Melnick, Ari https://orcid.org/0000-0002-8074-2287
Vyas, Paresh https://orcid.org/0000-0003-3931-0914
Ren, Bing https://orcid.org/0000-0002-5435-1127
Jeremias, Irmela
Psaila, Bethan https://orcid.org/0000-0001-8198-9663
Heckman, Caroline A. https://orcid.org/0000-0002-4324-8706
Blanco, M. Andrés https://orcid.org/0000-0003-4404-2301
Shi, Yang https://orcid.org/0000-0001-9713-1709
- License Information
-
More Information
Article History
Received: 10 December 2023
Accepted: 18 March 2025
First Online: 16 April 2025
Competing interests
: Y. Shi is a co-founder of K36 Therapeutics, Alternative Bio (ABio); a member of the Scientific Advisory Boards of K36 Therapeutics, ABio, Epigenica AB and Epic Bio; a board member of ABio and Epigenica AB; holds equity in Active Motif, K36 Therapeutics, Epic Bio, ABio and Epigenica AB; and serves on the Scientific Advisory Boards of School of Life Sciences, Westlake University and Westlake Laboratory of Life Sciences and Biomedicine, and Norway Centre for Embryology and Healthy Development. C.A.H. has received funding from Kronos Bio, Novartis, Oncopeptides, WNTResearch and Zentalis Pharmaceuticals for research unrelated to this study; and speaker and advisory fees from Amgen and Autolus. B.P. is a cofounder and equity holder in Alethiomics, a spin-out company from the University of Oxford; has received research funding from Alethiomics, Incyte and Galecto; and honoraria for consulting and/or paid speaking engagements from Incyte, Constellation Therapeutics, Blueprint Medicines, Novartis, GSK and BMS. All other authors declare no competing interests.
